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Melphalan 200 mg/m2 is the standard conditioning regimen for patients with multiple myeloma (MM) with
normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the
dose of melphalan and to improve the efﬁcacy, we designed a dose-escalation study of melphalan in
conjunction with palifermin in patients with NRF, with the hope that a higher dose of melphalan can be
administered with an acceptable degree of oral mucositis (OM). We enrolled 19 patients (18 evaluable) with
NRF. Dose-escalation of melphalan administered on day 2 began at 200 mg/m2 with palifermin admin-
istered at a ﬁxed dose of 60 mcg/kg/day. Palifermin was given as an i.v. bolus on day 5, 4, and 3, and
then on day þ1, þ2, and þ3. Subsequent dose escalations of melphalan were done at 20 mg/m2 increments
up to a maximum dose of 280 mg/m2. Of 18 evaluable patients, there were no treatment-related deaths by
day 100. The median age was 48.5 years (range, 33-65 years). The most common adverse events related to
palifermin included rash (18 events, no grade 3 events), elevation of amylase (10 events, 4 were grade 3
but asymptomatic), and lipase (5 events, 2 were grade 3 but asymptomatic), edema (11 events, no grade
3). The overall incidence of OM grade 3 was 44% (8/18) with a median duration of severe mucositis of 5
days (range, 3-6 days). Eleven patients (61%) required opioid analgesics. None of the patients received total
parenteral nutrition (TPN)/nasogastric feeding. Two of 6 patients who were given melphalan 280 mg/m2
did not develop OM. Cardiac dose-limiting toxicity (DLT) in the form of atrial ﬁbrillation did occur in 1 of 6
patients treated with melphalan 280 mg/m2. Palifermin has permitted safe dose escalation of melphalan up
to 280 mg/m2, thus reaching the cumulative dosage of melphalan administered in tandem ASCT. This
higher dose of melphalan has the potential to improve the efﬁcacy and, hopefully, outcomes of patients
with MM with a single ASCT. A phase 2 trial is necessary to better delineate the antimyeloma efﬁcacy of this
regimen.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous stem
cell transplant (ASCT) has shown improved progression-free
survival and reduced overall mortality compared to
conventional chemotherapy in patients with multiple
myeloma (MM) [1-5]. In patients with normal renal function
(creatinine clearance 60 mL/min/1.73 m2), melphalan
administered at a dose of 200 mg/m2 is considered
the standard conditioning regimen [6,7]. Melphalan has
a doseeresponse antimyeloma effect, and higher doses could
potentially improve outcomes when used as a conditioning
regimen for ASCT [8]. Attempts to improve response rates
have been made by intensiﬁcation of the conditioning
regimen. Unfortunately, these attempts have encounterededgments on page 60.
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gastrointestinal mucositis [9-12]. Moreau et al. [9] showed
that it is feasible to administer melphalan 220 mg/m2, but
signiﬁcant oral mucositis (OM), delayed platelet engraft-
ment, and cardiac arrhythmias were observed.
Attempts to minimize the incidence and severity of OM
have included the use of cytoprotective agents including
amifostine, which have allowed the dose of melphalan to be
increased to 280 mg/m2. Cardiac toxicity in the form of atrial
ﬁbrillation was seen in 3 of 36 patients treated with
melphalan doses 280 mg/m2 and was fatal in 1 patient
given melphalan 300 mg/m2 [13]. Amifostine has also been
associated with infusional toxicities, including hypotension
and nausea, and is currently not recommended for preven-
tion of OM in the setting of hematologic malignancies
[13-16]. Oral cryotherapy also reportedly reduces OM related
to high dose melphalan. Lilleby et al. [17] used oral cryo-
therapy in patients undergoing ASCT with melphalan 200
mg/m2. Although decreased incidence of OM was noticed in
this group, dose escalation of melphalan was not attempted.Transplantation.
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nocyte growth factor approved for the prevention of OM in
patients undergoing chemo/radiotherapy for hematological
malignancies [18-21]. Keratinocyte growth factor was origi-
nally derived from the embryonic lung ﬁbroblasts line and
has a target-speciﬁc mitogenic action on the epithelial cells.
Palifermin has been shown to decrease OM in patients taking
melphalan as the conditioning regimen for their trans-
plantation [22]. We have recently demonstrated that pal-
ifermin permitted safe dose escalation of melphalan up to
180mg/m2 in nondialysis-dependent myeloma patients with
creatinine clearance 60 mL/min/1.73 M2 [23]. The approx-
imate cost of palifermin is $4700 for a 5-mg vial. Palifermin
seems to be a costly option compared to oral cryotherapy, but
its use could be justiﬁed if dose escalation of melphalan is
achieved with acceptable toxicity and translates into
improve disease response. Palifermin can lead to decreased
toxicity related to melphalan, decreased hospital stays,
decreased use of total parenteral nutrition (TPN), and
narcotics, which further justiﬁes its cost. We have designed
this phase I dose escalation trial to determine the maximal
tolerated dose (MTD) of melphalan when used with pal-
ifermin in patients with normal renal function who were
undergoing ASCT for multiple myeloma (MM).
PATIENTS AND METHODS
This phase I trial was registered in the clinicaltrials.gov database
(NCT00482846). The study was conducted at Barbara Ann Karmanos Cancer
Institute, in Detroit, Michigan, approved by the Wayne State University
Institutional Review Board, and conducted in accordance with the Decla-
ration of Helsinki.
Study Design
Our primary objective was to determine the MTD of melphalan when
treated with palifermin in order to prevent OM in patients with normal
renal function who were undergoing ASCT for myeloma. Evaluation of
the efﬁcacy of this regimen, regimen-related toxicities, and the overall
response to therapy at day þ100 constituted the secondary objectives. This
study used the Common Toxicity Criteria (CTC), version 3.0, for adverse
event reporting [24].
This was a typical 3þ3 phase I design. Dose level 1 began at the
conventional transplantation dose of melphalan 200 mg/m2 with pal-
ifermin. Subsequent melphalan dose escalations were done at 20 mg/m2
increments in cohorts of 3 patients. Grade 4 OM, grade 4 diarrhea, and
grade 3 cardiac toxicity were considered DLT for melphalan; grade 3 or 4
hematological toxicity were considered expected due to ASCT. Grade 3 or
above skin rash and grade 4 symptomatic elevations in amylase and lipase
were considered DLT for palifermin. Improvement in incidence and severity
of OM was the experimental objective of the study, and initially at the time
of enrollment in level 1, grade 4 OM was not speciﬁed as DLT. Because of
safety concerns, the protocol was later amended and grade 4 OM was
considered a DLT. If no DLT events were noted within a cohort by day þ30Table 1
Oral Mucositis Assessment Scales
Grade 0 Grade 1 Grade 2
WHO No changes Soreness with erythema Erythema, ulcers,
NCI CTC (for BMT) Not applicable Painless ulcer or mild
soreness without a
lesion
Painful erythema
or ulcers,
but can swallow
Bearman criteria Not applicable Pain and/or ulceration
not requiring a
continuous i.v. narcotic
drug
Pain and/or ulcer
requiring a contin
narcotic drug
(morphine drip)
WHO indicates World Health Organization; NCI, National Cancer Institute; CTC, Coafter ASCT, the next cohort of 3 patients was enrolled at the next dose level.
Dose escalations were to stop if 2 DLT events occurred at a single
melphalan dose level, with that dose declared as the maximal administered
dose and the previous dose level as theMTD. If a single DLT event was noted,
3 additional patients were entered at that dose level, and dose escalation
proceeded only if no additional DLT events (ie, 1 of 6) were noted. If 1 or
more of these 3 additional patients have DLT, then dose escalation was
stopped, and this dose was to be declared the maximally administered dose
and the previous dose level as the MTD. If a full cohort of 3 patients was
entered at a given level without the observation of DLT, then dose escalation
to the next level was permitted. Based on severe cardiac toxicities noted at
melphalan 280 mg/m2 seen by Spencer et al. [13], we allowed dose esca-
lation only up to 280 mg/m2. A patient failing to receive all 6 palifermin
doses was declared ineligible and replaced on that dose level. Institution
guidelines were followed for apheresis and a minimum of 2.0  106 CD34þ
cells/kg were required to proceed to ASCT. The stem cell product was cry-
opreserved after apheresis and was reinfused according to standard prac-
tice. All study days are numbered with respect to the day of ASCT, which is
deﬁned as study day 0.
Eligibility
Patients were eligible if they qualiﬁed for ASCT per institutional criteria
and had at least 2.0  106 CD34þ cells/kg cryopreserved. Other require-
ments included an Eastern Cooperative Oncology Group performance status
of 2, MM stage 2/3, age 18 years, creatinine clearance >60 mL/min/
1.73 m2, total bilirubin <1.5  institutional upper limit of normal,
alanine aminotransferase and aspartate aminotransferase<3 institutional
upper limit of normal. Patients with baseline oral lesions, history of
allergic reactions to melphalan, or prior exposure to palifermin were
ineligible.
Dose calculations
The melphalan dose was calculated using the actual body weight (ABW)
except when the ABW was >40% above the ideal body weight (IBW), in
which case adjusted body weight (AdBW) was used: men: IBW
(kg)¼50þ 0.91 (height incm152);women: IBW(kg)¼45þ0.91 (height
in cm 152) andAdBW(kg)¼ IBWþ 0.25 (ABWe IBW). The palifermindose
was 60mcg/kg/day of ABWunless the patient’s ABWwas>40% above the IBW,
and then the AdBW was used for the dose. Palifermin was administered on
days5,4, and3, and thenrepeatedondayþ1,þ2, andþ3 (peripheral blood
stem cells were infused on day 0). There was a 24-hour interval between the
paliferminandmelphalanadministration (day2). Patients receivedpalifermin
as a once-daily i.v. bolus. No palifermin dose adjustments were allowed.
Filgrastimwas administered subcutaneously at a dose of 5mcg/kg/day, starting
on dayþ6 and continued until the absolute neutrophil count was>1500/mm3
for 3 consecutive days.
Patient monitoring and follow-up
Patients who received all 6 doses of palifermin were followed until
day þ100. Disease response to treatment was assessed on day þ28 and
day þ100(þ/7 days). Starting on day 2 with the administration of high-
dose melphalan, oral cavity assessments were performed by the bone
marrow transplant (BMT) attending daily using the World Health Organi-
zation (WHO) oral toxicity scale and continued until OM resolved
completely (WHO ¼ 0) or until day þ28, whichever came later (Table 1). If
a patient was discharged from the hospital without complete resolution of
OM, that patient was then followed twice weekly in the outpatient clinic by
the BMT attending until complete resolution.Grade 3 Grade 4
can eat solids Ulcers, liquid diet only Alimentation not possible
, edema, Painful erythema, edema,
or ulcers preventing
swallowing or requiring
hydrations or nutritional
support
Severe ulcerations requiring
prophylactic intubation or
resulting in documented
aspiration pneumonia
ation
uous i.v.
Severe ulceration and/or
mucositis requiring
preventative intubation,
or resulting in documented
aspiration pneumonia with
or without intubation
Death
mmon Toxicity Criteria; BMT, bone marrow transplant.
Table 3
Previous Treatment Regimen
Dose
Level
Disease
Status at
Transplantation
Pre-BMT Treatment Regimens
(Number of Cycles When Known)
1 PR Kyphoplasty, radiation, pulse
dexamethasone (4), lenalidomide/
dexamethasone/pamidronate
1 PD Melphalan/prednisone (5), thalidomide/
dexamethasone
1 PD Local radiation and spinal fusion,
thalidomide/dexamethasone (4)
2 PR Dexamethasone/zoledronic acid (3),
lenalidomide/dexamethasone
2 PD Radiation, laminectomy, lenalidomide/
dexamethasone/darbepoetin alpha
2 VGPR Vincristine/adriamycin/dexamethasone (4),
melphalan 200 mg/m2 with auto-PBSCT,
pamidronate, thalidomide/dexamethasone,
bortezomib (4), lenalidomide
3 VGPR Lenalidomide/dexamethasone (4),
bortezomib/dexamethasone (2)
3 CR Kyphoplasty, radiation, lenalidomide/
dexamethasone/zoledronic acid (6)
3 PR Adriamycin/bortezomib/dexamethasone/
zoledronic acid (4), lenalidomide/
dexamethasone (4)
4 PR Kyphoplasty, DVD (1), lenalidomide/
dexamethasone, bortezomib/
dexamethasone (3)
4 PR DVD (4)
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Patient Characteristics
Nineteen patients were enrolled between May 2007 and
September 2009. One patient was removed due to the
inability to receive all 6 doses of palifermin. This patient
received melphalan 200 mg/m2. The patient revoked his
consent after 4 doses of palifermin because he developed
grade 3 skin rash. No other grade 3 toxicity was observed
while the patient was enrolled in the study. The patient did
not develop any OM.
The baseline characteristics and previous treatment
regimen of the 18 evaluable patients are summarized in
Table 2 and Table 3, respectively. Eleven patients (61%) were
men, and the median age of the whole group was 48.5 years
(range, 33-65 years). The median creatinine clearance was
108 mL/min/1.73 m2 (range, 61-240). All patients had
a Karnofsky performance score 70%. The median number
of CD34þ infused was 4.78 cells/kg  106 (range, 2.18-
11.36). Melphalan was given in doses of up to and including
280 mg/m2 (n ¼ 6). All 18 patients were evaluable for
response at 100 days posttransplantation. The median
number of days for neutrophil engraftment was 12 (range,
10-13 days). The median number of days to platelet
engraftment was 19.5 (range, 0-29 days). The median
duration of hospitalization was 15.5 days (range, 14-22
days).4 PR DVD (6), lenalidomide/dexamethasone/
zoledronic acid (3)
5 VGPR Radiation, thalidomide/dexamethasone/
zoledronic acid (4)
5 CR Radiation, bortezomib/dexamethasone (4)
5 VGPR Bortezomib/lenalidomide/dexamethasone/
pamidronate (4)
5 VGPR Bortezomib/dexamethasone (1), bortezomib/
lenalidomide/dexamethasone (3)
5 VGPR Radiation, lenalidomide/dexamethasone/
zoledronic acid (4)
5 SD Surgery, DVD (3), lenalidomide/bortezomib/Mucositis Occurrences
The overall incidence of, and OM grade 3 was 44% (8 of
18 patients) the median time to resolution of any OM was
10 days (range, 4-20 days) (Table 4). The median duration of
severe OM was 5 days (range, 3-6 days). Grade 4 OM was
seen in only 1 patient at level 1 (melphalan 200 mg/m2),
lasting 3 days. Accrual was allowed to the next level as
grade 4 OM was not deﬁned as DLT at the time of accrual inTable 2
Patient Characteristics
Sex: male (%) 11 (61)
Median age (range) 48.5 (33-65)
Race: white 15 (83)
Median creatinine clearance (range) 108 (61-240)
Durie-Salmon stage: no. (%)
Stage 2 7 (39)
Stage 3 11 (61)
Isotypes: No. (%)
IgG kappa 7 (39)
IgG lambda 2 (11)
IgA kappa 5 (28)
IgA lambda 1 (6)
Kappa light chain 1 (6)
Lambda light chain 1 (6)
Nonsecretory 1 (6)
Previous radiation 4 (22)
Karnofsky performance scale: no. (%)
70 2 (11)
80 7 (39)
90 9 (50)
Disease status at the time of transplantation: No. (%)
VGPR 6 (33)
PD 3 (17)
CR 2 (11)
PR 6 (33)
SD 1 (6)
Median duration of hospital stay (range) 15.5 (14-22)
VGPR indicates very good partial response; PD, progressive disease; CR,
complete remission; PR, partial remission; SD, stable disease.
dexamethasone (4)
BMT indicates bone marrow transplant; PR, partial remission; PD, progres-
sive disease; VGPR, very good partial response; PBSCT, peripheral blood stem
cell transplantation; CR, complete remission; DVD, doxil/vincristine/
dexamethasone.level 1, which was later amended. Five of 18 patients
developed no OM. None of the patients needed TPN
including the level 1 patient with grade 4 OM. Only 1 of 6
patients enrolled in level 5 (melphalan 280 mg/m2) suffered
from grade 3 OM.Adverse Events
The patients were monitored for side effects related
to melphalan and palifermin (Table 5). The most common
adverse events related to palifermin included rash (18 events,
no grade 3 events), elevation of amylase (10 events, 4 were
grade 3 asymptomatic), lipase (5 events, 2 were grade 3
asymptomatic), and edema (11 events, no grade 3 events).
Cardiac toxicity (DLT) in the form of atrial ﬁbrillation, which
could be related to melphalan, occurred in 1 of 6 patients
treated with melphalan 280 mg/m2. Three more patients
were added to that dose level with no recurrences of that
toxicity. Eleven patients (61%) required opioid analgesics;
none needed TPN/nasogastric feeding. Other adverse events
related to the treatment were vomiting, which was reported
in 15 patients, and diarrhea was observed in 13 patients.
Grade 3 diarrhea was seen in 2 patients. Five of the 13
Table 4
Melphalan Dose and Severity of OM
Patients WHO-OM
Score Range
Duration of
Severe OM
(Grade 3)*
Days to
Resolution
of OM
Level 1 ¼ melphalan 200
1* 2-4 5 9
2 1-2 - 8
3 1-3 6 10
Level 2 ¼ melphalan 220
4 0 - -
5 1-3 5 10
6 2-3 6 11
Level 3 ¼ melphalan 240
7 0 - -
8 1-3 5 12
9 1-2 - 12
Level 4 ¼ melphalan 260
10 0 - -
11 1-3 6 20
12 2-3 5 16
Level 5 ¼ melphalan 280
13 0 - -
14 0-1 - 4
15 0-1 - 8
16 1-2 - 10
17 1-3 3 17
18 0 - -
OM indicates oral mucositis; WHO, World Health Organization.
* Only 1 patient in the whole group receiving melphalan 200 mg/m2
developed grade 4 OM for 3 days.
Table 6
Disease Response
Dose Level # Dose of
Melphalan
Disease Status at
Transplantation
Disease Status
at Day 100
1 200 PR CR
1 200 PD PR
1 200 PD SD
2 220 PR PR
2 220 PD SD
2 220 VGPR SD
3 240 VGPR VGPR
3 240 CR CR
3 240 PR PR
4 260 PR PR
4 260 PR VGPR
4 260 PR SD
5 280 VGPR SD
5 280 CR CR
5 280 VGPR SD
5 280 VGPR PR
5 280 VGPR SD
5 280 SD VGPR
PR indicates partial remission; CR, complete remission; PD, progressive
disease; SD, stable disease; VGPR, very good partial response.
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of 13 patients had positive blood cultures. No infection-
related death was noted. The highest allowable level 5 in our
study received melphalan 280 mg/m2. Further dose escala-
tion was not allowed because of cardiac toxicity reported at
melphalan 300 mg/m2 in earlier studies [13]. Hence, we did
not reach the maximal administered dose.Response
The responses to treatment are shown in Table 6.
Complete responsewas seen in 3 patients. Two patients were
given maintenance treatment within the 100-day follow-up
period. No deaths were observed at 100 days post-
transplantation. There was no treatment-related death.
Tumor responses have been noted at all melphalan doses.Table 5
Adverse Events
Grade 1 Grade 2 Grade 3 Grade 4
Palifermin-Related Adverse Effects: No. of Patients (%)
Skin rash 7 (39) 11 (61) 0 0
Elevated amylase 5 (28) 1 (6) 4 (22) 0
Elevated lipase 3 (17) 2 (11) 0 0
White coating of
the tongue*
15 (83)
Edema* 11 (61)
Melphalan and ASCT-Related Adverse Effects: No. of Patients
Diarrhea 5 (28) 6 (33)
(3 had C. diff)
2 (11)
(2 had C. diff)
0
Vomiting 12 (67) 3 (17) 0 0
Cardiac toxicity 0 0 1 (6)
(atrial ﬂutter)
0
Positive blood
cultures*
5 (28)
ASCT indicates autologous stem cell transplant; C. diff, Clostridium difﬁcile.
* Not graded.DISCUSSION
The curative treatment of MM remains elusive. Although
high-dose chemotherapy followed by ASCT has shown
improved survival rates, relapse continues to limit long-
term survival. Mucosal barrier injury (MBI) is a major cause
of morbidity and mortality in patients with MM undergoing
ASCT with melphalan as a conditioning regimen [25,26].
Effective muco-protection could be a way to intensify the
dose of melphalan, as was seen in our study. We were able
to escalate the melphalan safely up to 280 mg/m2 in
patients with normal renal function by addition of pal-
ifermin. Our study results are in accordance with the
retrospective study by Kobbe et al. [22] who showed
improved incidence of OM when using a 3-day course of
palifermin before ASCT with melphalan 200 mg/m2. Earlier,
we demonstrated that the melphalan dose could be safely
increased up to 180 mg/m2 in patients with chronic kidney
disease. Incidence of severe OM observed in our study was
better as compared to other studies reported in patients
with chronic kidney disease [23].
The incidence of grade 3 OM was 44% in our study.
Moreau et al. [7] demonstrated an incidence of severe OM
(grade >3) as 42% in newly diagnosed patients with MM
conditioned with melphalan 200 mg/m2. Another study
using melphalan 220 mg/m2 showed an incidence of grade 4
mucositis as 63% [9]. We consider the incidence of grade 3 or
above OM in our group of previously treated patients
acceptable, as the median duration of severe OM was only 5
days (range, 3-6 days) and the patients were able to have
liquid diets (WHO grade 3). Therefore, none of the patients in
our study needed TPN. The need for TPN use was determined
by the rounding physician based on multiple factors,
including but not limited to incidence/severity of diarrhea,
nausea, vomiting, functional capacity, and electrolyte
disturbances. Eleven patients needed narcotics for pain
relief, but theywere not considered candidates for TPN based
on the above-mentioned factors.
DLT in the form of atrial ﬁbrillationwas noted in a patient
receiving a melphalan dose of 280 mg/m2. Further dose
escalationwas stopped and the next 3 patients were enrolled
at the same dose level. In the 3 additional patients, no DLTs
were seen and 280 mg/m2 was declared the MTD. Dose
M.H. Abidi et al. / Biol Blood Marrow Transplant 19 (2013) 56e6160escalation beyond 280 mg/m2 was not allowed in our trial
becausemelphalan 300mg/m2 had shown cardiotoxicity and
related mortality in earlier trials [13]. Clostridium difﬁcile
toxinwas isolated from stool in 5 of 18 patients. Five patients
had positive blood cultures in our study. There was no
infection-related death. MBI can lead to an increased rate of
neutropenic infections and treatment-related mortality
[27,28]. Cytoprotective action of palifermin on MBI could
have a potential role in decreasing the rate of invasive
infection. Palifermin through its preventive role as a muco-
protective agent can lead to lower rates of infection and
better nutritional intake, which could lead to improved
overall outcome for patients with myeloma who are under-
going ASCT and justify the cost of palifermin. The usefulness
of this agent could be further enhanced by combining it with
cryotherapy, which by itself has shown to improve OM [17].
Lilleby et al. [17] had demonstrated muco-protective action
of oral cryotherapy in patients with MM undergoing ASCT
with melphalan 200 mg/m2. Their study was not designed
for dose escalation. TPN, when needed, was administered for
a median of 2 days (range, 0-15 days). They used the National
Cancer Institute (NCI) CTC criteria for OM assessment [17].
It does seem that there is a remarkable grading difference
in OM assessment scales, making comparison of protective
beneﬁt across trials difﬁcult (Table 1). As mentioned above,
Lilleby et al. [17] used NCI CTC criteria for OM assessment.
According to NCI criteria, TPN usewill result in grading of OM
as grade 3, whereas according to the WHO scale (Table 1),
TPN use will likely categorize the patient as grade 4 OM.
Similarly, Spencer et al. [13] had used Seattle (Bearman)
criteria to assess OM in their dose escalation trial with ami-
fostine, in which grade 4 toxicity was death. We decided to
use the WHO scale because this scale seems to combine both
objective ﬁndings by examination (ulceration and redness)
and functional capacity such as inability to eat solid food or
no food at all.
Moreover, this scale was the primary scale used in the
pivotal trial by Spielberger et al. [21], which led to approval of
palifermin for the prevention of OM in patients undergoing
chemo/radiotherapy for hematological malignancies.
Palifermin seems to be well tolerated in multiple studies.
The common side effects, which have been previously noted
with palifermin, were also encountered in our study. These
included a white coating of the tongue, rash, edema, and
elevated amylase and lipase [19-21]. Meropol et al. [20] re-
ported elevated amylase in 48 of 54 patients and lipase in 50
of 54 patients treated with varying doses of palifermin.
Higher elevations were noted at higher doses. In the study by
Spielberger et al. [21], common side effects reported by
palifermin recipients were rash (55%), pruritus (50%),
erythema (47%), cough (34%), and edema (29%). Asymp-
tomatic increase in amylase and lipase was also noted. These
side effects are manifestations of its physiological action of
stimulating the growth of epithelial cells [29]. There was no
DLT secondary to palifermin use in our study. Our study
suggests that palifermin given at a dose of 60 mcg/kg/day for
3 days before conditioning and 3 days after the ASCT allowed
a melphalan dose escalation to 280 mg/m2 in patients with
MM with normal renal function. Augmented cell killing may
be achieved with doses of melphalan above what has been
given historically without palifermin, thus breaking the
present-day barriers of DLTs in ASCT. Our trial was a dose-
ﬁnding trial and the primary objective was to determine the
MTD of melphalanwhen used in conjunctionwith palifermin
in patients with normal renal function (NRF) who areundergoing ASCT for MM. A phase 2 trial is necessary to
better delineate the antimyeloma efﬁcacy of this combina-
tion in terms of safety proﬁle and clinical responses. We
recommend using palifermin with melphalan 280 mg/m2,
which was the MTD determined by our trial. Modiﬁcation of
palifermin dosing could also be tried with or without
combining it with other agents.ACKNOWLEDGMENTS
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